Sfoglia per Autore
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy
2018 Saponaro, C; Sergio, S; Coluccia, A; De Luca, M; La Regina, G; Mologni, L; Famiglini, V; Naccarato, V; Bonetti, D; Gautier, C; Gianni, S; Vergara, D; Salzet, M; Fournier, I; Bucci, C; Silvestri, R; Passerini, C; Maffia, M; Coluccia, A
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer
2018 Redaelli, S; Ceccon, M; Zappa, M; Geeta, G; Mastini, C; Mauri, M; Nigoghossian, M; Massimino, L; Cordani, N; Farina, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Novel targeted therapeutics for MEN2
2018 Redaelli, S; Plaza-Menacho, I; Mologni, L
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells
2018 Mologni, L
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
2018 Ceccon, M; Mauri, M; Massimino, L; Giudici, G; Piazza, R; Gambacorti-Passerini, C; Mologni, L
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition
2017 Mologni, L; Magistroni, V; Casuscelli, F; Montemartini, M; GAMBACORTI PASSERINI, C
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients
2017 Mologni, L; Piazza, R; Khandelwal, P; Pirola, A; Gambacorti-Passerini, C
RET kinase inhibitors: a review of recent patents (2012–2015)
2017 Mologni, L; GAMBACORTI PASSERINI, C; Goekjian, P; Scapozza, L
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
2017 Awad, M; Mastini, C; Patino, R; Mologni, L; Voena, C; Mussolin, L; Mach, S; Adeni, A; Lydon, C; Janne, P; Chiarle, R
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
2017 Awad, M; Mastini, C; Blasco, R; Mologni, L; Voena, C; Mussolin, L; Mach, S; Adeni, A; Lydon, C; Sholl, L; Jänne, P; Chiarle, R
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead
2017 Mologni, L; Dalla Via, M; Chilin, A; Palumbo, M; Marzaro, G
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates
2017 Farina, F; Ceccon, M; Mori, S; Verga, L; Borin, L; Mologni, L; Fontana, D; Geeta, G; Piazza, R; Gambacorti-Passerini, C
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
2016 Redaelli, S; Ceccon, M; Antolini, L; Rigolio, R; Pirola, A; Peronaci, M; GAMBACORTI PASSERINI, C; Mologni, L
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
2016 Ceccon, M; Merlo, M; Mologni, L; Poggio, T; Varesio, L; Menotti, M; Bombelli, S; Rigolio, R; Manazza, A; Di Giacomo, F; Ambrogio, C; Giudici, G; Casati, C; Mastini, C; Compagno, M; Turner, S; GAMBACORTI PASSERINI, C; Chiarle, R; Voena, C
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications
2016 Ardini, E; Menichincheri, M; Banfi, P; Bosotti, R; De Ponti, C; Pulci, R; Ballinari, D; Ciomei, M; Texido, G; Degrassi, A; Avanzi, N; Amboldi, N; Saccardo, M; Casero, D; Orsini, P; Bandiera, T; Mologni, L; Anderson, D; Wei, G; Harris, J; Vernier, J; Li, G; Felder, E; Donati, D; Isacchi, A; Pesenti, E; Magnaghi, P; Galvani, A
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis
2016 Piazza, R; Mologni, L; Ramazzotti, D; Spinelli, R; Pirola, A; De Sano, L; Ferrari, P; Magistroni, V; Sharma, N; Khandelwal, P; Gambacorti-Passerini, C
Targeting drug resistance mutations: Discovery of EUD-GK-91 chemical series
2016 Zuccotto, F; Angiolini, M; Bernardi, A; Airaghi, F; Mologni, L; Mcdonald, N; Epemolu, O; Read, K
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D
Efficacy of a cancer vaccine against ALK-rearranged lung tumors
2015 Voena, C; Menotti, M; Mastini, C; Di Giacomo, F; Longo, D; Castella, B; Merlo, M; Ambrogio, C; Wang, Q; Minero, V; Poggio, T; Martinengo, C; D'Amico, L; Panizza, E; Mologni, L; Cavallo, F; Altruda, F; Butaney, M; Capelletti, M; Inghirami, G; Jänne, P; Chiarle, R
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; GAMBACORTI PASSERINI, C
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile